Objective: To evaluate clinical effect of Tangzhiping in treating patients of metabolic syndrome (MS) with phlegm and blood stasis syndrome. Method: Eighty cases of MS who met the research standards were randomly divided into the treatment group and the control group. Lifestyle interventions were given to both groups

Tangzhiping (3 g

bid) was used for the treatment group

and metformin tablets (0.25 g

tid) for the control group. The fasting blood glucose (FPG)

2 hours plasma glucose(2 hPG)

glycosylated hemoglobin (HbA1c)

total cholesterol (TC)

low density lipoprotein cholesterol(LDL-C)

high density lipoprotein cholesterol(HDL-C)

triglyceride (TG)

systolic blood pressure (SBP)

diastolic blood pressure (DBP)

fasting insulin (FINS)

homeostasis model assessment of insulin resistance (HOMA-IR)

weight

waist circumference (WC)

body mass index (BMI) and clinical symptoms changes were compared between two groups after three months. Result: There months after treatment

the total efficiency on clinical syndrome in the treatments group was as high as 86.84%

higher than that of the control group of 56.76% (P<0.05). The treatment group could reduce FPG

2 hPG

HbA1c

FINS

TC

TG

LDL-C

SBP and weight

and improve insulin resistance (P<0.05)

especially in blood-lipid regulation

blood pressure decreased

clinical symptom improvement

the treatment group was significantly better than the control group (P<0.05). Conclusion: Tangzhiping can significantly regulate glucose-lipid disorder for MS patients with phlegm and blood stasis syndrome

and it is a safe and effective.